Biocon mulls merger of wholly owned subsidiary

19 Jul 2012 Evaluate

Biocon, a Bangalore-based Pharma company is looking for merger of its wholly-owned subsidiary Biocon Biopharmaceuticals with itself. The company will take the final decision on July 25 in a meeting of the Board of Directors of the company, a day before the company’s Annual General Meeting.

Biocon Biopharmaceuticals was established as a joint venture with a Cuban partner in 2003 to provide manufacturing support for biopharmaceuticals, and then became a wholly-owned subsidiary of Biocon in April 2010.

Biocon is Asia’s leading R&D based Biotechnology Company. It produces anti-diabetic agents like Acarbose, Pioglitazone, Repaglinides and Rosiglitazone. In the biological segment it produces Insulin, Erythropoietin (EPO), Filgrastim (GCSF), Streptokinase and Monoclonal Antibodies.

 

Biocon Share Price

318.80 -1.85 (-0.58%)
29-Apr-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.80
Dr. Reddys Lab 1176.25
Cipla 1541.00
Lupin 2067.40
Zydus Lifesciences 887.95
View more..
© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.
×
Please wait your portfolio is updating...